Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Lipoic Acid Series	276.48M
Lipoic Acid Series Growth	-26.25%
Irecoxib	62.98M
Irecoxib Growth	835.06%
Carnosine Series	45.45M
Carnosine Series Growth	-24.09%
Phosphatidylcholine Series	41.09M
Phosphatidylcholine Series Growth	-1.26%
Other Business	3.46M
Other Business Growth	-44.10%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
China	218.24M
China Growth	20.31%
Foreign	211.23M
Foreign Growth	-31.39%